Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6H8JM)

Drug Name
Ro-04-6790 Drug Info
Synonyms
Ro 04-6790; 202466-68-0; Ro-04-6790; CHEMBL433461; Ro-046790; 4-amino-N-[2,6-bis(methylamino)pyrimidin-4-yl]benzenesulfonamide; 4-Amino-N-(2,6-bis-methylamino-pyrimidin-4-yl)-benzenesulfonamide; 4-amino-N-(2,6-bis(methylamino)pyrimidin-4-yl)benzenesulfonamide; JELFWSXQTXRMAJ-UHFFFAOYSA-N; Ro 4-6790; NCGC00015885-01; 4-Amino-N-[2,6-bis(methylamino)-4-pyrimidinyl]benzenesulfonamide Dihydrobromide; Lopac-R-140; AC1NSM3L; Biomol-NT_000164; Lopac0_001045; GTPL274; SCHEMBL678897; BPBio1_000551; CTK8E8508; CHEBI:92762; ZINC23472
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5312145
ChEBI ID
CHEBI:92762
CAS Number
CAS 202466-68-0
TTD Drug ID
DM6H8JM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 6 receptor (HTR6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LU AE58054 DMWGRQD Schizophrenia 6A20 Phase 3 [3]
SB-742457 DM6L4ZT Alzheimer disease 8A20 Phase 3 [4]
AVN 211 DMVB4OS Schizophrenia 6A20 Phase 2/3 [5]
SYN120 DMDF7XB Parkinson disease 8A00.0 Phase 2 [6]
AVN 101 DMJFLBC Alzheimer disease 8A20 Phase 2 [5]
SYN-120 DMPW0UL Alzheimer disease 8A20 Phase 2 [7]
PF-05212377 DMPVQYR Alzheimer disease 8A20 Phase 2 [8]
AVN 322 DMK2LGM Cognitive impairment 6D71 Phase 2 [4]
SAM-531 DMHVJZ6 Alzheimer disease 8A20 Phase 2 [9]
SUVN-502 DMQD753 Alzheimer disease 8A20 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 6 receptor (HTR6) TTJS8PY 5HT6R_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 274).
2 Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87.
3 Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
4 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
5 Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
6 Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
7 The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
8 PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
9 Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
10 Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.